Subscribe to our Email Alerts


John Lambert PhD GAICD

Chief Executive Officer and Managing Director

John has more than 16 years of drug discovery and development experience. His appointments include leadership roles in Drug Development, Operations Management and Drug Discovery (Biota Pharmaceuticals), as Senior Director (Medicines Development for Global Health) and as an academic researcher in medicinal and biological chemistry (University of Melbourne, ANU and Harvard University).

He is an experienced manager of both in early and late development of therapeutics and has built and led multidisciplinary project teams tasked with the objective of delivering clinical proof-of-concept for new products. As such, his experience spans the entire spectrum of drug development from design of development strategy through project management, manufacture, formulation, pre-clinical and clinical development and regulatory affairs.

John joined Amplia Therapeutics as Operations Manager in August 2018 and was appointed as CEO on 24 June 2019 and Managing Director on 6 February 2020.

Mark Devlin B. Sc. (Hons) PhD GradD Drug Dev

Chief Scientific Officer

After obtaining a PhD in Pharmacology from the University of Melbourne, Mark has worked in a variety of roles focused on drug discovery and development in a number of therapeutic areas including, pain, inflammation, autoimmune disease and oncology. Mark worked at the Peter MacCallum Cancer Centre between 2008 and 2018 in a number of roles for the CRC for Cancer Therapeutics (CRC), first as Head of the CRC’s Translational Cancer Biology Laboratory and later as Director of Translational Cancer Biology for the CRC. In his role as a lead scientist, Mark and his team were involved in the PRMT5 program that was licensed by the CRC to MSD, in 2016 and the Chromatin-Modifying Enzyme programs licensed to Pfizer Inc in 2018.

Mark was also the Biology Leader on the CRC Programs that delivered AMP945 and AMP886 that are now being developed by Amplia.

In addition to his scientific experience, Mark has held a number of business-facing roles as COO of the CRC where he led due-diligence activities between the CRC and Pfizer and later as CEO and Managing Director of the commercial partner in the CRC, CTxONE Pty Ltd. Mark is an honorary Associate Professor in the Department of Pharmacology at the University of Melbourne, and has a Graduate Diploma in Drug Development from the University of New South Wales and an MBA from the Melbourne Business School.

Rhiannon Jones BSC (Hons) PhD

Director, Operations

Rhiannon has a background in research operations and project management and more than 10 years of experience in the medical research and biotechnology sector. Rhiannon has previous appointments as Director, Operations and Governance (Cancer Therapeutics CRC), Project Manager (WEHI, Business Development Office), Scientific Coordinator (WEHI, Inflammation Division) and a postdoctoral researcher in organic chemistry (Monash University, Chemistry Department). Her experience includes project management, communications, policy development and oversight, ethics committee submissions, risk management and staff professional development systems.

Rhiannon has a PhD in chemistry and a BSc(Hons) from the University of Adelaide and a Certificate in Governance Practice from the Governance Institute of Australia.

Jeff Carter B. Fin. Admin, M. App. Fin., CA

Chief Financial Officer

Mr Carter has been the Chief Financial Officer of Amplia Therapeutics Limited since 2013 and has more than 30 years of expertise in professional accounting, investment banking, corporate finance and commercial / strategic planning roles. He has served as a member of the board on a USA based company. He was the chief financial officer of the company until it’s move to the USA at the end of 2009. Since the beginning of 2000 he has served as chief financial officer and company secretary of various publicly listed healthcare companies. Prior to his move into the healthcare sector he also held senior positions with Coca Cola, Santos, Canadian Imperial Bank of Commerce and Touche Ross.